Policy Comments
The priority legislative and regulatory issues that the Cancer Policy Institute focuses on are driven by policy pillars that are centered around the values, needs, and preferences of individuals impacted by cancer. We work in conjunction with patients, patient advocacy organizations, medical associations, and other stakeholders to advance policies aimed at improving access to, affordability of, and quality of care across the cancer continuum.
Letter expressing support for the Reducing Hereditary Cancer Act (H.R.1526/S.765) which would expand access to genetic testing for individuals with a history or suspected history of a hereditary cancer gene mutation and would expand coverage for risk-reduction.
Letters urging the inclusion of the PASTEUR Act in any moving legislative vehicle this year, including the reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA).
Letter in response to the National Committee for Quality Assurance's (NCQA) opportunity to comment on their ongoing work to address gaps in cancer screening and quality measurement for transgender, gender-diverse, and intersex populations.
Letter to HHS in response to the Medicare Program Contract Year 2024 Proposed Rule that addresses health equity in Medicare Advantage and utilization management requirements.
Letter to HHS supporting Delaware’s decision to reinstate retroactive coverage for all Medicaid beneficiaries.
Letter urging HHS to approve the requests for inclusion of continuous eligibility for parent and caretaker relatives (12 months), and for children aging out of the Children’s Health Insurance Program (CHIP) to improve health equity among other outcomes.
Letter opposing the Oklahoma’s continued waiver of three-month retroactive coverage. Retroactive coverage prevents gaps in coverage by allowing individuals who are eligible for Medicaid to begin treatment prior to officially receiving their coverage determination.
Letter to HHS supporting Rhode Island's request for pre-release services for justice-involved populations, supporting expanded postpartum coverage, and opposing the continued waiver of retroactive coverage.
Letter thanking the original House sponsors of the HELP Copays Act (H.R. 830) and pledging support to help pass the bill.
Letter to CMS in response to the Contract Year 2024 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs proposed rule that addresses expanded eligibility for low-income subsidy benefit under Part D, making the Limited Income New Eligible Transition demonstration permanent, changing the Medical Therapy Management program, aligning Part C and Part D Special Enrollment Periods with Medicare exceptional condition enrollment, and failure to collect and incorrect collections of Part D premiums and cost-sharing amounts.